Summary
Di Wu is a bioinformatics and protein design leader with nine years of industry experience delivering therapeutic antibodies from discovery through clinical candidate selection. He combines hands-on expertise in phage/yeast display, hybridoma and single B-cell sequencing with structural biology, Python-driven data pipelines, and deep learning to accelerate antibody engineering across modalities. As a group leader at organizations including Pfizer, Henlius, and now Eli Lilly, he has led interdisciplinary teams that moved molecules into Phase I trials and built AI-enabled discovery platforms. Known for integrating experimental and computational workflows, he often designs the informatics to close the loop between NGS data, structural models, and wet-lab optimization. Based in San Diego, he brings a rare blend of academic postdoctoral depth and pragmatic industry delivery that consistently advances programs toward clinical development.
9 years of coding experience
14 years of employment as a software developer
PhD Biochemistry, PhD Biochemistry at Arizona State University
Postdoctoral Researcher Structural based protein Engineering immunotherapy, Postdoctoral Researcher Structural based protein Engineering immunotherapy at Stanford University School of Medicine
Postdoc Structural Biology, Postdoc Structural Biology at Tsinghua University
English, Chinese